Citations

Clear

1413 citation(s) found for "To, Christina".

Mechanosensitive Piezo Channels Contribute to Airway Changes in Chronic Obstructive Pulmonary Disease
Migulina, Nataliya , Roos, Benjamin, Borghuis, Theo, Ngassie, Maunick Lefin Koloko , Drake, Li Y. , Timens, Wim , Vogel, Elizabeth R. , Pabelick, Christina M. , Roos, Ben, Koloko Ngassie, Maunick Lefin , Drake, Li , Brandsma, Corry-Anke , Burgess, Janette K , Prakash, Y S , Pabelick, Christina M , Vogel, Elizabeth R , Timens, Wim , Roos, B., Brandsma, Corry‐Anke , Burgess, Janette K. , Prakash, Y. S.

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.14.732150 | PMID 42367887 Get It

Abstract As an intrinsically mechanosensitive organ, the lung experiences a range of mechanical forces. Chronic obstructive pulmonary disease (COPD) involves abnormal macroscopic cellular and extracellular matrix (ECM) changes that impact mechanical properties of the lung. Mechanosensitive Piezo1/2 channels are expressed in the lung including on airway smooth muscle cells (ASM) that mediate cellular responses to stretch and ECM biomechanics. The expression and roles of Piezos in COPD lung ASM are not known. We hypothesized that Piezo expression and activation are altered in COPD lung ASM influencing ECM regulation. Distribution of Piezo proteins in ASM and epithelium of small airways of COPD stage II and IV vs. non-COPD controls was assessed using immunohistochemistry and ImageJ (n=10-17/group). Isolated ASM cells from control (n=6) vs. COPD stage II and IV patients (n=3 each stage) were exposed to stretch or the Piezo1 agonist Yoda1 followed by measurement of ECM gene and protein expression. Less Piezo2 staining was observed in COPD IV patients compared to controls, with lesser area and intensity of staining in the epithelial layer, and lower intensity of staining in ASM and small airways as a whole. Fura-2-based imaging of ASM Ca 2+ showed lower influx after Yoda1 exposure in COPD II compared to control and COPD IV. Gene expression of Piezo1 increased upon stretching in controls but not in COPD ASM, while Piezo2 protein expression decreased with stretching in all groups. Yoda1 treatment resulted in decreased collagen1 , fibulin1 and periostin gene and collagen 1 and periostin protein expression in ASM. Overall, these results support a role for Piezo activation in abnormal ECM-ASM cell crosstalk in COPD.
Correcting spatial transcriptomics data affected by a prevalent transcript leakage problem across platforms, species, and tissues
Shi, Christina Huan , Zhai, Yibo, Chow, Savio Ho-Chit , Flores, Jesus, Kern, Colin , Adams, Peter D, Ren, Bing, Zhu, Quan, Carver, Chase M., Yip, Kevin Y , Carver, Chase Matthew , Teneche, Marcos G. , Ren, Bing , Schafer, Marissa , Wei, Yingying , Yip, Kevin Y.

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.13.732076 | PMID 42367830 Get It

Abstract Spatial transcriptomics has been widely applied to study the spatial distribution of cell types, cell states, and specific gene expression in tissue samples. However, we show that there is a prevalent transcript leakage problem in spatial transcriptomics data, where transcripts expressed by a cell diffuse to its neighborhood and are recurrently detected in the nearby cells. By analyzing published data sets, we show that this problem is general across data produced from different tissues and different species using different imaging-based and sequencing-based spatial transcriptomics platforms. It affects both upstream tasks such as expression quantification as well as downstream tasks such as cell-type annotation and detection of spatially-dependent gene expression. To tackle the transcript leakage problem, we propose a reference-free Bayesian model-based method, DeLeakage, which cleans up the data much more effectively than existing denoising methods. DeLeakage also improves cell-type annotation and avoids false detection of spatially dependent expression.
Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
Braun, David, Dana, Nicholas, Hernan, Hilary R., Scribano, Christina, Johnson, Christin , Vedder, Lindsey, Euw, Erika von , Zweng, Julie, Wargowski, Ellen, Sunil, Aishwarya , Sharma, D, Routh, Josh, Rexroad, Katherine, McDonnell, Payton , Jergens, Victor, Costa, Catarina, Zuniga, Richard, Patel, Paras M., Martin, Robert C.G., Majeed, Umair, Mukhopadhyay, Debabrata, Lou, Yanyan, Kokabi, Nima, Jakub, James W., Hays, David, Godwin, Andrew K., Giffi, Victoria, Gelbard, Alexander, Friedl, Andreas, Duimstra, Emma Kate, Dronca, Roxana S., Chen, Ruqin, Chalfin, Heather, Broome, Barbara , Babiker, Hani M., Chandra, Tarun, Caenepeel, Sean, Hrycyniak, Laura , Sood, Chetan , Ramos, Hilario, Patel, Premal , Advani, Pooja, Gierman, Hinco J., Taube, Janis, Braun, David , Sahni, Shalini, Scribano, Christina M. , Wargowski, Ellen , Zuniga, Richard, Toia, Giuseppe V. , Martin, Robert C.G. , Majeed, Umair , Mukhopadhyay, Debabrata , Lou, Yanyan , Kokabi, Nima , Jakub, James W. , Godwin, Andrew K. , Gelbard, Alexander , Friedl, Andreas , Dronca, Roxana , Chen, Ruqin, Chalfin, Heather J., Babiker, Hani M. , Caenepeel, Sean , Ramos, Hilario J. , Patel, Premal, Advani, Pooja , Gierman, Hinco J. , Taube, Janis M

Mayo Clinic

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.05.26354635 Get It

Summary Functional ex vivo assays using live tumor tissues have demonstrated strong predictive accuracy for response to immune checkpoint inhibitors (ICIs) but are not scalable, requiring manual processing of large resections collected at academic centers. Here, an ex vivo live tumor fragment (LTF) platform was developed using standard-of-care biopsies from 228 patients with suspected malignancy collected across prospective, multicenter observational trials and biobanks. Hierarchical clustering of ICI-mediated changes in cytokine production identified two groups: responders and nonresponders. A binary classifier (elive index) using 8 cytokines achieved an AUC of 0.99 for cluster prediction. elive index correctly predicted clinical benefit in 93% (26/28) of patients ( P = 3.2x10 -5 ) and accurately identified 83% (10/12) of objective responders. Critically, elive responders were identified among biomarker-negative patients, highlighting the platform as a scalable approach that complements existing companion diagnostics and expands the population of patients identified to benefit from ICI therapy.
Single-cell spatial transcriptomics of formalin-fixed, paraffin-embedded biopsies reveals colitis-associated cell networks
Mennillo, Elvira , Lotstein, Madison L. , Lee, Gyehyun , Hou, Julian H., Johri, Vrinda , Ekstrand, Christina , Tsui, Jessica, He, Jun , Mahadevan, Uma, Oh, David Y., Kattah, Michael G, Lotstein, Madison , Leet, Donna , Eckalbar, Walter L. , Gill, Ryan M. , Bowman, Christopher , Fragiadakis, Gabriela K. , Kattah, Michael G. , Combes, Alexis J.

Mayo Clinic

Journal of Clinical Investigation | June 9, 2026 | Volume: 136 | Issue: 14 | Pages: No page available

10.1172/jci202488 | PMID 42262875 Get It

Imaging-based, single-cell, spatial transcriptomics (iSCST) of FFPE tissue enables comprehensive analysis of archived specimens while preserving spatial context, critical to an understanding of ulcerative colitis (UC) pathology. Here, we deployed a robust framework for applying iSCST to clinical FFPE mucosal biopsies from patients with UC or immune checkpoint inhibitor–induced colitis, as well as patients serving as healthy controls. iSCST using custom Xenium gene panels enabled precise detection of diverse cell subsets and disease-specific genes. We mapped transcriptionally distinct fibroblast subsets within mucosal niches, including inflammation-associated fibroblasts (IAFs), and identified colitis-specific neighborhoods formed by IAFs, monocytes, and neutrophils. Transcriptional signatures and spatial neighborhoods uncovered through iSCST were associated with vedolizumab (VDZ) response, with nonresponders exhibiting either an innate IAF-monocyte-neutrophil signature or adaptive gut-associated lymphoid tissue signature, while responders showed enrichment of an epithelial cellular neighborhood. These signatures were validated in an internal and an external dataset, supporting the existence of 2 distinct archetypes of treatment resistance to VDZ in UC. This iSCST framework provides a powerful approach for analyzing FFPE tissues, offering insights into colitis-associated cellular networks and identifying biomarkers to enhance patient risk stratification in routine clinical workflows.
Beyond Breathing: Lung as a Sensory Organ A Report from the NHLBI Workshop on Lung Sensing and its Implication in Diseases
Jendzjowsky, Nicholas, Kuo, Christin S. , Chen, Zhijian, Li, Peng, Prescott, Sara , Liu, Yin, Seeholzer, Laura, Tschumperlin, Daniel J. , Taylor‐Clark, Thomas E. , Rajagopal, Jay, Haber, Adam L, Noel, A, Kotas, Maya, Drake, M G, Pabelick, C M, Rosenblatt, Jody , Mouradian, Gary, Su, Yujuan, Gomez, Christian, Lin, Q. , Lu, Qing , Mongodin, Emmanuel F. , Vuga, Louis, Zhou, Guofei , Prakash, Y S, Sun, X, Pabelick, Christina, Jendzjowsky, Nicholas Gregory , Reznikov, Leah R. , Li, Peng, Prescott, Sara, Seeholzer, Laura F. , Rajagopal, Jayaraj , Haber, Adam L., Kotas, Maya E. , Pabelick, Christina M. , Mouradian, Gary Charles , Gómez, Christian R. , Vuga, Louis J., Prakash, Y. S.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | June 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrcmb/aanag111 | PMID 42265991 Get It

Abstract The lung, one the largest branching organs in our body and vital for survival at first breath, is commonly known as the gas-exchange organ. Recent novel findings on lung sensing cells, molecules, and lung-brain crosstalk in the emerging discipline of interoception have highlighted the consideration of the lung as a sensory organ. Acknowledging the central importance of lung sensing to human health and disease, NHLBI convened a workshop to synthesize the past, current, and future of lung sensing research, with in-person presentations by ∼20 interdisciplinary experts and a large virtual audience. Here, we highlight the key topics discussed and summarize a blueprint for the future in this important field.
Successful Management of BRAF V600E–Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy
Hoyek, Celine , Pirozzi, Angelo, Rone, Kelley, Wu, Christina, Jones, Jeremy, Bekaii-Saab, Tanios, Pirozzi, Angelo , Rone, Kelley , Jones, Jeremy C , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 4, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.7003 | PMID 42242284 Get It

The recent approval of encorafenib, cetuximab, and FOLFOX based on the phase III BREAKWATER trial has introduced a new standard of care for the first-line treatment of BRAF V600E–mutated metastatic colorectal cancer (mCRC). However, its safety and efficacy in patients with significant liver dysfunction remains unclear and, as such, patients are often excluded from pivotal clinical trials. This report presents a case of BRAF V600E–mutated mCRC presenting with extensive hepatic involvement and liver dysfunction. Despite the absence of guidelines, the patient was initiated on full-dose encorafenib, cetuximab, and FOLFOX. He experienced a rapid clinical and biochemical response, with near-normalization of liver enzymes after cycle 1, and complete functional recovery by cycle 3. Treatment was well tolerated, with no significant adverse events throughout 9 cycles. He subsequently transitioned to maintenance 5-FU, cetuximab, and encorafenib. Posttreatment blood-based next-generation sequencing revealed no residual actionable mutations. The patient then successfully underwent complete surgical resection of his primary tumor and metastatic disease with negative margins. This case highlights the importance of considering encorafenib-based therapy in select patients with BRAF V600E–mutated mCRC in the setting of compromised liver function.
Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.
O'Sullivan, Ciara Catherine, Kalinsky, Kevin, Yau, C, Wallace, Anne M., Chien, Jo, Yee, D, Nanda, Rita, Isaacs, C, Omene, Coral, Kulkarni, T, Swigart, Lamorna Brown, Perlmutter, J, Hylton, N, Borowsky, Alexander D., Rugo, H S, Veer, Laura van't, Esserman, L J, O’Sullivan, Ciara C. , Kalinsky, Kevin M. , Yau, Christina , Yee, Douglas , Boughey, Judy C. , Borges, Virginia F. , Isaacs, Claudine , Omene, Coral , Kulkarni, Tejaswini , Swigart, Lamorna Brown , Hylton, Nola, Shatsky, Rebecca , Veer, Laura J. van’t

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba514 Get It

LBA514 Background: Preclinical and clinical data show that antibody-drug conjugates (ADCs) such as T-DXd may synergize with immunotherapy. Rilvegostomig (R) is a monovalent, Fc-reduced, dual checkpoint bispecific IgG1 monoclonal antibody against PD-1 and TIGIT receptors. R + T-DXd was evaluated as neoadjuvant therapy for up to 4 cycles. Methods: I-SPY2.2 is a phase II neoadjuvant trial with three neoadjuvant sequences (Blocks A/B/C). All HER2-negative subtypes were eligible for R + T-DXd in Block A. Predicted responders at the end of Block A or B could undergo surgery; otherwise, they continued to Block B +/- C. Block B pts received paclitaxel +/- carboplatin +/- pembrolizumab and Block C pts doxorubicin + cyclophosphamide (AC) +/- pembrolizumab, HR+ immune+ received IO in Blocks B/C. Results are analyzed by receptor and response predictive subtypes (RPS), that include expression-based immune, and luminal signatures with hormone receptor (HR) and HER2 status. Some pts were randomized to a control regimen (skipping R + T-DXd in block A and starting in block B). To minimize risk of interstitial lung disease (ILD) that could lead to treatment discontinuation, pts underwent pulmonary function tests and high-resolution chest CTs every 6 weeks. Abnormalities were reviewed in real time. The primary endpoint was pathologic complete response (pCR), within each RPS and HR/HER2 signature, with estimated pCR (EpCR) rates compared to subtype-specific block A goal rates and control pts in those groups. Other endpoints included safety and treatment discontinuation. Results: 105 pts were treated with R + T-DXd in block A, while 31 pts were randomized to the control regimen. Block A EpCR rate was 57% in the 12 HR+Immune+ pts vs a pre-specified goal of 15% (posterior probability, PP > .99). In 35 HR-Immune+ pts EpCR was 52% vs a pre-specified goal of 40% (PP = .87). No other groups (Immune-) had a PP > .85 for their respective pCR goal rate. HER2-IHC was 0 (27.6%), 1+ (49.5%) and 2+ (22.9%) in the treatment arm vs. 37.7%, 37.7%, and 24.7% in the control arm, with no difference in distribution between arms in immune subtypes. The most common adverse events in Block A were fatigue (84.8%), nausea (81.0%) and alopecia (58.1%). ILD was the most common adverse event of special interest in Block A and overall, occurring in 12 pts (11.4%; 7G1, 4G2, 1G3) during Block A and in 3 pts (G1, 2.9%) in other Blocks. 8 pts discontinued T-DXd + R due to ILD and proceeded to the next Block. Conclusions: When considering the full treatment strategy including block B and C regimens, experimental strategies had similar EpCR rates vs. controls in immune+ subtypes but block A rates exceeded pre-defined goal thresholds. This infers that treatment beginning with R + T-DXd has equivalent efficacy to standard of care for immune+ pts, but 64% pts with pCR skip chemotherapy (Block B) and 97% avoid AC (Block C). R + T-DXd participants avoided persistent ILD. Clinical trial information: NCT01042379 .